Form 4: Pfizer Director James C. Smith Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director James C. Smith reports acquisition of phantom stock units representing deferred director's compensation.
Summary
- On March 28, 2024, James C. Smith, a director of Pfizer Inc., acquired 1,621.622 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $27.75.
- Following the transaction, Smith directly owns 120,440.112 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a transaction related to director compensation. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
This filing is a routine disclosure of a director's compensation in the form of phantom stock units, which is a common practice in corporate governance.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it relates to director compensation.
Key Dates
| Date | Description |
|---|---|
| 03/28/2024 | Date of transaction: Acquisition of phantom stock units. |
| 04/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.